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Introduction: An intranasal gel dosage formulation of scopolamine (INSCOP) 
was developed for the treatment of Space Motion Sickness (SMS), which is 
commonly experienced by astronauts during space missions. The 
bioavailability and pharmacokinetics (PK) were evaluated under IND 
guidelines. Since information is lacking on the effect of gender on the PK of 
Scopolamine, we examined gender differences in PK parameters of INSCOP at 
three dose levels of 0.1, 0.2 and 0.4 mg.
Methods: Plasma scopolamine concentrations as a function of time data were 
collected from twelve normal healthy human subjects (6 male/6 female) who 
participated in a   fully randomized double blind crossover study. The PK 
parameters were derived using WinNonlin.  Covariate analysis of PK profiles 
was performed using NONMEN and statistically compared using a likelihood 
ratio test on the difference of objective function value (OFV). Statistical 
significance for covariate analysis was set at P<0.05(ΔOFV=3.84).
Results:  No significant difference in PK parameters between male and female 
subjects was observed with 0.1 and 0.2 mg doses. However, CL and Vd were 
significantly different between male and female subjects at the 0.4 mg dose.
Results from population covariate modeling analysis indicate that a one-
compartment PK model with first-order elimination rate offers best fit for 
describing INSCOP concentration-time profiles.  The inclusion of sex as a 
covariate enhanced the model fitting (ΔOFV=-4.1) owing to the gender-
dependent CL and Vd differences after the 0.4 mg dose. 
Conclusion:  Statistical modeling of scopolamine concentration-time data 
suggests gender-dependent pharmacokinetics of scopolamine at the high dose 
level of 0.4 mg. Clearance of the parent compound was significantly faster and 
the volume of distribution was significantly higher in males than in females, 
As a result, including gender as a covariate to the pharmacokinetic model of 
scopolamine offers the best fit for PK modeling of the drug at dose of 0.4 mg 
or higher.
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Space Motion Sickness (SMS) is an age old problem for astronauts on both 
short and long duration space flights.
Scopolamine (SCOP) is the most frequently used drug for the treatment of 
motion sickness (MS) which is currently available in transdermal patch and 
tablet dosage forms; these formulations of SCOP are ineffective for the 
treatment of SMS.
Intranasal dosage forms are noninvasive with rapid absorption and enhanced 
bioavailability, thus allowing precise and reduced dosing options alongside 
the suitability for rescue and treatment.
An intranasal gel dosage formulation of scopolamine (INSCOP) was 
developed, and bioavailability and pharmacokinetics (PK) were evaluated 
under approved protocol in IND guidelines.
With the increase number of female astronauts participating in space missions, 
it is crucial to characterize gender differences of PK to ensure the safety and 
efficacy of INSCOP
Scopolamine
Figure 1. Chemical Structure of Scopolamine 
After the forward stepwise selection and 
backward elimination steps, sex was selected 
to add to the final model which had 
significant influence on clearance and the 
volume of distribution of INSCOP.
 We determined the population pharmacokinetic model for INSCOP and established the gender-
dependent pharmacokinetics of scopolamine. 
 Clearance of the parent compound was significantly faster and the volume of distribution was 
significantly higher in males than in females, As a result, including gender as a covariate to the 
pharmacokinetic model of scopolamine offers the best fit for PK modeling of the drug at dose of 0.4 
mg or higher.
In order to elucidate the effect of gender on the PK of 
Scopolamine, we examined gender differences in PK parameters 
of INSCOP at three dose levels of 0.1, 0.2 and 0.4 mg.
Treatments: 
 Twelve healthy human subjects (6 male/6 female) 
participated in the study.  
 A randomized double blind crossover study design was 
used with a seven-day washout period between 
treatments.
 Serial blood samples (7 ml) were collected at 0, 0.083, 
0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24 h after each 
treatment.
 Blood samples were gently mixed by inversion and 
centrifuged at 3000 rpm to separate plasma, which was 
transferred into cryotubes and stored frozen at -40ºC until 
analysis.
Sample Analysis: 
 Separation and quantification of SCOP concentrations in 
the sample extracts was achieved using a Waters Acquity
UPLC system combined with Micromass Quattro Micro 
API MA/MS detector using an electrospray interface.
 Positive ions were monitored in the Multiple Reaction 
Monitoring (MRM) mode.
 Chromatographic separation was accomplished with an 
Agilent Zorbax SB-CN 50 x 2.1 mm, 5 μ, column.
 Mobile phase : 90:10 (v/v), methanol:2 mM ammonium 
acetate, pH adjusted to 5.0±0.1, with a flow rate of 0.2 
mL/min, injection volume of 10 μL, and run time of 4 
minutes.
Data Analysis: 
 Individual pharmacokinetic analysis was performed using 
WinNonlin (version 3.3) by 1-compartment model to 
obtain pharmacokinetic parameters. 
 Differences of individual pharmacokinetic parameters 
between male and female were tested using student T-test. 
A customary levels of significance of α=0.05 for 
significance testing was used.
 Population pharmacokinetic analysis was performed by 
NONMEN (version7.0).
 Sex, body weight, age were employed as covariates in the 
model selection.
 Model selection was based on goodness-of-fit in addition to 
criteria(OFV) of statistical significance.
 Statistical significance for base model building and 
individual covariate analysis was set at 
P<0.05{Δ(OFV)=3.84}.
Population Pharmacokinetics Individual Estimation
Parameters Dose=0.4 mg
(Mean±SE) Unit Base model Covariate model Male Female P value
N 12 6 Male/6 Female 6 6
OFV 1297.8 1293.7 <0.05 (ΔOFV>3.84)
AIC 1315.8 1307.8
tvKa /hr 1.0±0.03  0.97±0.03  2.09±1.75 0.99±0.68 0.18
tvV L/kg 4.6±0.59  6.8±1.0  14.77±7.33 6.72±3.03 0.03
tvCl L/(hr*kg) 4.7±0.57  5.3±0.7  6.78±1.68 4.29±1.68 0.03
dCldSEX1 NA ‐0.26
dVdSEX1 NA ‐0.52
Table 2 Prediction of PK Parameters from Base Model and  Gender Covariate Model
Fig. 2  Goodness of Fit Plot of Base Model(DV – Observed 
concentration, PRED-Population Predicted concentration)
Fig. 3  Goodness of Fit Plot after Covariate Modeling (DV – Observed 
concentration, PRED-Population Predicted concentration)
Fig. 5 Weighted Residuals versus Population Prediction Profile for 
Gender Covariate Model
Fig. 4 Weighted Residuals versus Population Prediction Profile for 
Base Model
Gender Male Female
Age (Mean ± SD) 37 ± 8.5 29 ± 5.4
Body weight 
(Mean ± SD) 88.7 ± 9.6 72.8 ± 14.3
Average BMI 26
Table 1 Demographics of 12 Subjects
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